CRIS Live signals | Maximize Profits with Getagraph.com

BUY 102906 min ago

@ $10.44

Issued: 13 Feb 2024 @ 10:07

Return: 41.44%

Previous signal: Feb 12 - 13:04

Previous signal: Sell

Return: -6.09 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States...

Stats
Today's Volume	4 653.00
Average Volume	33 677.00
Market Cap	87.06M
EPS	$0 ( 2024-02-08 )
Next earnings date	( $-1.940 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.650
ATR14	$0.120 (0.82%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-01	Zung Jonathan B.	Buy	500 000	Employee stock option (right to buy)
2023-05-01	Zung Jonathan B.	Buy	0
2023-01-23	Kaitin Kenneth I	Buy	85 000	Non Qualified Stock Option
2023-01-23	Hohneker John	Buy	85 000	Non Qualified Stock Option
2023-01-23	Rubin Marc	Buy	85 000	Non Qualified Stock Option

INSIDER POWER
85.85
Last 97 transactions
Buy: 14 857 117 \| Sell: 1 304 959

Curis Inc Correlation

10 Most Positive Correlations
BUR	0.887
ARCT	0.884
PSTV	0.882
IFRX	0.882
EZFL	0.878
VTSI	0.866
SBET	0.864
MDRR	0.861
FRSX	0.86
LGMK	0.859

10 Most Negative Correlations
AMRB	-0.912
PKOH	-0.886
SMH	-0.881
SNCY	-0.873
GPRE	-0.85
VOXX	-0.846
VTRU	-0.833
PSCC	-0.831
PSEC	-0.828
HLNE	-0.828

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Curis Inc Financials

Annual	2023
Revenue:	$10.02M
Gross Profit:	$9.81M (97.88 %)
EPS:	$-8.96

Q4	2023
Revenue:	$2.70M
Gross Profit:	$2.54M (94.14 %)
EPS:	$-2.04

Q3	2023
Revenue:	$2.83M
Gross Profit:	$2.77M (97.88 %)
EPS:	$-2.13

Q2	2023
Revenue:	$2.20M
Gross Profit:	$2.12M (96.63 %)
EPS:	$-2.47

Financial Reports:

No articles found.

Curis Inc

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.